Sequestosome 1/p62: across diseases

References

• Alves-Rodrigues A, Gregori L, Figueiredo-Pereira ME. (1998). Ubiquitin, cellular inclusions and their role in neurodegeneration. Trends Neurosci 21:516–520.
   PubMed Web of Science ®Google Scholar
• Babu JR, Geetha T, Wooten MW. (2005). Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94:192–203.
   PubMed Web of Science ®Google Scholar
• Bardag-Gorce F, Riley NE, Nan L, Montgomery RO, Li J, French BA, Lue YH, French SW. (2004). The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation. Exp Mol Pathol 76:9–16.
   PubMed Web of Science ®Google Scholar
• Braak H, Thal DR, Del Tredici K. (2011). Nerve cells immunoreactive for p62 in select hypothalamic and brainstem nuclei of controls and Parkinson’s disease cases. J Neural Transm 118:809–819.
   PubMed Web of Science ®Google Scholar
• Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. (2003). Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 424:797–801.
   PubMed Web of Science ®Google Scholar
• Cavey JR, Ralston SH, Sheppard PW, Ciani B, Gallagher TR, Long JE, Searle MS, Layfield R. (2006). Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget’s disease of bone. Calcif Tissue Int 78:271–277.
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. (2002). Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359:2072–2077.
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM. (1996). The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 19:1190–1193.
   PubMed Web of Science ®Google Scholar
• Copple IM, Lister A, Obeng AD, Kitteringham NR, Jenkins RE, Layfield R, Foster BJ, Goldring CE, Park BK. (2010). Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J Biol Chem 285:16782–16788.
   PubMed Web of Science ®Google Scholar
• Donohue TM Jr, Kharbanda KK, Casey CA, Nanji AA. (2004). Decreased proteasome activity is associated with increased severity of liver pathology and oxidative stress in experimental alcoholic liver disease. Alcohol Clin Exp Res 28:1257–1263.
   PubMed Web of Science ®Google Scholar
• Du Y, Wooten MC, Wooten MW. (2009). Oxidative damage to the promoter region of SQSTM1/p62 is common to neurodegenerative disease. Neurobiol Dis 35:302–310.
   PubMed Web of Science ®Google Scholar
• Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, Porollo A, Hansen M, Moscat J, Diaz-Meco MT. (2011). p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol Cell 44:134–146.
   PubMed Web of Science ®Google Scholar
• Durán A, Serrano M, Leitges M, Flores JM, Picard S, Brown JP, Moscat J, Diaz-Meco MT. (2004). The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6:303–309.
   PubMed Web of Science ®Google Scholar
• Fataccioli V, Andraud E, Gentil M, French SW, Rouach H. (1999). Effects of chronic ethanol administration on rat liver proteasome activities: Relationship with oxidative stress. Hepatology 29:14–20.
   PubMed Web of Science ®Google Scholar
• Garner TP, Long J, Layfield R, Searle MS. (2011). Impact of p62/SQSTM1 UBA domain mutations linked to Paget’s disease of bone on ubiquitin recognition. Biochemistry 50:4665–4674.
   PubMed Web of Science ®Google Scholar
• Geisler S, Holmström KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W. (2010). PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 12:119–131.
   PubMed Web of Science ®Google Scholar
• Giasson BI, Lee VM. (2001). Parkin and the molecular pathways of Parkinson’s disease. Neuron 31:885–888.
   PubMed Web of Science ®Google Scholar
• Goedert M. (2001). α-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492–501.
   PubMed Web of Science ®Google Scholar
• Goode A, Layfield R. (2010). Recent advances in understanding the molecular basis of Paget disease of bone. J Clin Pathol 63:199–203.
   PubMed Web of Science ®Google Scholar
• Hayes JD, McMahon M. (2009). NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer. Trends Biochem Sci 34:176–188.
   PubMed Web of Science ®Google Scholar
• Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, Watanabe S, Ando J, Iwadate M, Yamamoto M, Lee MS, Tanaka K, Komatsu M. (2011). Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 193:275–284.
   PubMed Web of Science ®Google Scholar
• Jain A, Lamark T, Sjøttem E, Larsen KB, Awuh JA, Øvervatn A, McMahon M, Hayes JD, Johansen T. (2010). p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 285:22576–22591.
   PubMed Web of Science ®Google Scholar
• Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, Wright A, Zhang M, You J, Sun SC. (2008). Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 118:1858–1866.
   PubMed Web of Science ®Google Scholar
• Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A. (2009). Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137:721–735.
   PubMed Web of Science ®Google Scholar
• Joazeiro CA, Weissman AM. (2000). RING finger proteins: Mediators of ubiquitin ligase activity. Cell 102:549–552.
   PubMed Web of Science ®Google Scholar
• Joung I, Strominger JL, Shin J. (1996). Molecular cloning of a phosphotyrosine-independent ligand of the p56lck SH2 domain. Proc Natl Acad Sci USA 93:5991–5995.
   PubMed Web of Science ®Google Scholar
• Keller JN, Hanni KB, Markesbery WR. (2000). Impaired proteasome function in Alzheimer’s disease. J Neurochem 75:436–439.
   PubMed Web of Science ®Google Scholar
• Komatsu M, Ichimura Y. (2010). Physiological significance of selective degradation of p62 by autophagy. FEBS Lett 584:1374–1378.
   PubMed Web of Science ®Google Scholar
• Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, Yamamoto M. (2010). The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12:213–223.
   PubMed Web of Science ®Google Scholar
• Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S, Hamazaki J, Nishito Y, Iemura S, Natsume T, Yanagawa T, Uwayama J, Warabi E, Yoshida H, Ishii T, Kobayashi A, Yamamoto M, Yue Z, Uchiyama Y, Kominami E, Tanaka K. (2007). Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131:1149–1163.
   PubMed Web of Science ®Google Scholar
• Kovalenko A, Chable-Bessia C, Cantarella G, Israël A, Wallach D, Courtois G. (2003). The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination. Nature 424:801–805.
   PubMed Web of Science ®Google Scholar
• Kuusisto E, Salminen A, Alafuzoff I. (2001a). Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 12:2085–2090.
   PubMed Web of Science ®Google Scholar
• Kuusisto E, Salminen A, Alafuzoff I. (2002). Early accumulation of p62 in neurofibrillary tangles in Alzheimer’s disease: Possible role in tangle formation. Neuropathol Appl Neurobiol 28:228–237.
   PubMed Web of Science ®Google Scholar
• Kuusisto E, Suuronen T, Salminen A. (2001b). Ubiquitin-binding protein p62 expression is induced during apoptosis and proteasomal inhibition in neuronal cells. Biochem Biophys Res Commun 280:223–228.
   PubMed Web of Science ®Google Scholar
• Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, Sun Z, White E, Zhang DD. (2010). A noncanonical mechanism of Nrf2 activation by autophagy deficiency: Direct interaction between Keap1 and p62. Mol Cell Biol 30:3275–3285.
   PubMed Web of Science ®Google Scholar
• Laurin N, Brown JP, Morissette J, Raymond V. (2002). Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70:1582–1588.
   PubMed Web of Science ®Google Scholar
• Layfield R, Cavey JR, Najat D, Long J, Sheppard PW, Ralston SH, Searle MS. (2006). p62 mutations, ubiquitin recognition and Paget’s disease of bone. Biochem Soc Trans 34:735–737.
   PubMed Web of Science ®Google Scholar
• Layfield R, Ciani B, Ralston SH, Hocking LJ, Sheppard PW, Searle MS, Cavey JR. (2004). Structural and functional studies of mutations affecting the UBA domain of SQSTM1 (p62) which cause Paget’s disease of bone. Biochem Soc Trans 32:728–730.
   PubMed Web of Science ®Google Scholar
• Lowe J, Mayer J, Landon M, Layfield R. (2001). Ubiquitin and the molecular pathology of neurodegenerative diseases. Adv Exp Med Biol 487:169–186.
   PubMed Web of Science ®Google Scholar
• Lu M, Nakamura RM, Dent ED, Zhang JY, Nielsen FC, Christiansen J, Chan EK, Tan EM. (2001). Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol 159:945–953.
   PubMed Web of Science ®Google Scholar
• Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, Dipaola RS, Karantza-Wadsworth V, White E. (2009). Autophagy suppresses tumorigenesis through elimination of p62. Cell 137:1062–1075.
   PubMed Web of Science ®Google Scholar
• Michou L, Collet C, Laplanche JL, Orcel P, Cornélis F. (2006). Genetics of Paget’s disease of bone. Joint Bone Spine 73:243–248.
   PubMed Web of Science ®Google Scholar
• Morales-Piga AA, Rey-Rey JS, Corres-González J, García-Sagredo JM, López-Abente G. (1995). Frequency and characteristics of familial aggregation of Paget’s disease of bone. J Bone Miner Res 10:663–670.
   PubMed Web of Science ®Google Scholar
• Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y. (1993). Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10:1151–1160.
   PubMed Web of Science ®Google Scholar
• Moscat J, Diaz-Meco MT. (2000). The atypical protein kinase Cs. Functional specificity mediated by specific protein adapters. EMBO Rep 1:399–403.
   PubMed Web of Science ®Google Scholar
• Moscat J, Diaz-Meco MT. (2011). Feedback on fat: P62-mTORC1-autophagy connections. Cell 147:724–727.
   PubMed Web of Science ®Google Scholar
• Nakaso K, Yoshimoto Y, Nakano T, Takeshima T, Fukuhara Y, Yasui K, Araga S, Yanagawa T, Ishii T, Nakashima K. (2004). Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: Possible mechanisms and the role in Lewy body formation in Parkinson’s disease. Brain Res 1012:42–51.
   PubMed Web of Science ®Google Scholar
• Okada K, Yanagawa T, Warabi E, Yamastu K, Uwayama J, Takeda K, Utsunomiya H, Yoshida H, Shoda J, Ishii T. (2009). The α-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice. Hepatol Res 39:490–500.
   PubMed Web of Science ®Google Scholar
• Okatsu K, Saisho K, Shimanuki M, Nakada K, Shitara H, Sou YS, Kimura M, Sato S, Hattori N, Komatsu M, Tanaka K, Matsuda N. (2010). p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria. Genes Cells 15:887–900.
   PubMed Web of Science ®Google Scholar
• Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G, Johansen T. (2007). p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 282:24131–24145.
   PubMed Web of Science ®Google Scholar
• Perry G, Friedman R, Shaw G, Chau V. (1987). Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA 84:3033–3036.
   PubMed Web of Science ®Google Scholar
• Ramesh Babu J, Lamar Seibenhener M, Peng J, Strom AL, Kemppainen R, Cox N, Zhu H, Wooten MC, Diaz-Meco MT, Moscat J, Wooten MW. (2008). Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem 106:107–120.
   PubMed Web of Science ®Google Scholar
• Riley BE, Kaiser SE, Shaler TA, Ng AC, Hara T, Hipp MS, Lage K, Xavier RJ, Ryu KY, Taguchi K, Yamamoto M, Tanaka K, Mizushima N, Komatsu M, Kopito RR. (2010). Ubiquitin accumulation in autophagy-deficient mice is dependent on the Nrf2-mediated stress response pathway: A potential role for protein aggregation in autophagic substrate selection. J Cell Biol 191:537–552.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Durán A, Selloum M, Champy MF, Diez-Guerra FJ, Flores JM, Serrano M, Auwerx J, Diaz-Meco MT, Moscat J. (2006). Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab 3:211–222.
   PubMed Web of Science ®Google Scholar
• Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. (2004). Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 24:8055–8068.
   PubMed Web of Science ®Google Scholar
• Shin J. (1998). P62 and the sequestosome, a novel mechanism for protein metabolism. Arch Pharm Res 21:629–633.
   PubMed Web of Science ®Google Scholar
• Spataro V, Norbury C, Harris AL. (1998). The ubiquitin-proteasome pathway in cancer. Br J Cancer 77:448–455.
   PubMed Web of Science ®Google Scholar
• Stumptner C, Fuchsbichler A, Heid H, Zatloukal K, Denk H. (2002). Mallory body–a disease-associated type of sequestosome. Hepatology 35:1053–1062.
   PubMed Web of Science ®Google Scholar
• Sundaram K, Shanmugarajan S, Rao DS, Reddy SV. (2011). Mutant p62P392L stimulation of osteoclast differentiation in Paget’s disease of bone. Endocrinology 152:4180–4189.
   PubMed Web of Science ®Google Scholar
• Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K, Mizushima N. (2011). Autophagy-deficient mice develop multiple liver tumors. Genes Dev 25:795–800.
   PubMed Web of Science ®Google Scholar
• Terry RD, Masliah E, Hansen LA. (1999). The neuropathology of Alzheimer disease and the structural basis of its cognitive alteractions. In: Terry RD, Katzman R, Bick KL, Sisodia SS (eds). Alzheimer Disease, 2nd edn, New York: Lippincott Williams & Wilkins, pp. 187–206.
   Google Scholar
• Thompson HG, Harris JW, Wold BJ, Lin F, Brody JP. (2003). p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene 22:2322–2333.
   PubMed Web of Science ®Google Scholar
• Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. (2003). CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 424:793–796.
   PubMed Web of Science ®Google Scholar
• Tybl E, Shi FD, Kessler SM, Tierling S, Walter J, Bohle RM, Wieland S, Zhang J, Tan EM, Kiemer AK. (2011). Overexpression of the IGF2-mRNA binding protein p62 in transgenic mice induces a steatotic phenotype. J Hepatol 54:994–1001.
   PubMed Web of Science ®Google Scholar
• Vadlamudi RK, Shin J. (1998). Genomic structure and promoter analysis of the p62 gene encoding a non-proteasomal multiubiquitin chain binding protein. FEBS Lett 435:138–142.
   PubMed Web of Science ®Google Scholar
• Visconti MR, Langston AL, Alonso N, Goodman K, Selby PL, Fraser WD, Ralston SH. (2010). Mutations of SQSTM1 are associated with severity and clinical outcome in paget disease of bone. J Bone Miner Res 25:2368–2373.
   PubMed Web of Science ®Google Scholar
• Wooten MW, Geetha T, Babu JR, Seibenhener ML, Peng J, Cox N, Diaz-Meco MT, Moscat J. (2008). Essential role of sequestosome 1/p62 in regulating accumulation of Lys63-ubiquitinated proteins. J Biol Chem 283:6783–6789.
   PubMed Web of Science ®Google Scholar
• Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A, Denk H. (2002). p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 160:255–263.
   PubMed Web of Science ®Google Scholar